Recent news highlights analyst coverage initiation and maintenance of positive recommendations by multiple firms, strategic collaborations, and product development updates.

• Clear Street initiated coverage of Cellectis S.A. with a Buy recommendation in December 2025 [N2].
• Citizens maintained an Outperform recommendation for Cellectis S.A. in December 2025 [N3].
• Jefferies maintained a Buy recommendation for Cellectis S.A. in December 2025 [N4].
• Barclays maintained an Overweight recommendation for Cellectis S.A. in October 2025 [N6].
• Cellectis announced a 'Smart CAR T' strategy at AACR-IO 2025 aimed at enhancing efficacy against solid tumors [N8].
• The company charted its course for 2025 with a boost from its collaboration deal with AstraZeneca [N7].
• Search interest in Cellectis stock has spiked recently, indicating increased market attention [N1].

Cellectis leverages advanced gene-editing technology to develop allogeneic CAR T-cell therapies that could transform cancer treatment by providing off-the-shelf products with improved safety and efficacy. Its strategic collaboration with AstraZeneca and ongoing clinical trials for proprietary UCART candidates demonstrate active pipeline development. The company’s liquidity position supports continued investment in research, development, and manufacturing. Positive analyst coverage and recent strategic initiatives, such as the 'Smart CAR T' strategy, indicate market interest and potential for innovation in solid tumor therapies.

Cellectis operates in a high-risk, capital-intensive sector with no approved products generating material revenues. The company has a history of net losses and an accumulated deficit, reflecting ongoing investment without profitability. Patent litigation risks, including ongoing lawsuits alleging infringement of TALEN technology patents, pose potential legal and financial challenges. The company’s current liquidity, while sufficient for near-term operations, depends on successful capital raises and collaborations. Delays or failures in clinical development, regulatory approvals, or manufacturing scale-up could adversely impact its business prospects.

Cellectis' moat is based on its proprietary gene-editing technology platform enabling the development of allogeneic CAR T-cell therapies, which are designed to be off-the-shelf and potentially more cost-effective than autologous therapies. Its collaborations with established pharmaceutical companies, such as AstraZeneca, provide strategic partnerships and revenue streams. The company's focus on next-generation immunotherapies with enhanced safety and efficacy features, along with its in-house manufacturing capabilities, contribute to its competitive positioning. However, as a clinical-stage company, its moat is contingent on successful clinical development, regulatory approvals, and protection of intellectual property.

• Patent Litigation Risk: Cellectis faces ongoing patent infringement litigation related to its TALEN-based gene editing technology, which could result in costly legal proceedings and impact its ability to develop or commercialize certain products [S1].
• Clinical Development Uncertainty: As a clinical-stage company, Cellectis' future depends on successful clinical trials and regulatory approvals, which are inherently uncertain and may require significant additional investment [S1].
• Financial Sustainability: The company has incurred significant net losses and has an accumulated deficit, requiring continued access to capital markets or collaborations to fund operations beyond current liquidity [S1].
• Dependence on Collaborations: Cellectis derives substantial revenues from collaboration agreements, particularly with AstraZeneca, making it reliant on partners for funding and development progress [S1].
• Currency and Market Risks: The company operates internationally with revenues in U.S. dollars but expenses primarily in Euros, exposing it to foreign exchange risks [S1].

• Cellectis S.A. is a clinical-stage biotechnology company focused on gene-editing technologies to develop allogeneic UCART product candidates in immuno-oncology and gene therapy candidates in other therapeutic areas [S1].
• The company’s UCART candidates are gene-edited T-cells expressing chimeric antigen receptors (CARs) designed to target cancers, with an emphasis on allogeneic, off-the-shelf products derived from healthy donors [S1].
• Cellectis aims to develop CAR T-cell therapies with enhanced safety and efficacy features, including control properties to prevent attack on healthy tissues and resistance to immune inhibition [S1].
• The company manages its operations in a single Therapeutics segment focused on immuno-oncology and monogenic diseases since June 2023 after deconsolidation of Calyxt [S1].
• Cellectis has collaboration and license agreements, notably a joint research and collaboration agreement (JRCA) with AstraZeneca, which is a significant source of revenue [S1].
• The company is sponsoring clinical studies for two proprietary UCART candidates: BALLI-01 and NATHALI-01 [S1].
• Cellectis has incurred net losses historically, including a net loss attributable to shareholders of $67.6 million for the year ended December 31, 2025, with adjusted net loss (excluding non-cash stock-based compensation) of $61.5 million [S1].
• For the year ended December 31, 2025, revenues were $72.9 million, mainly from the AstraZeneca JRCA and other license agreements [S1].
• As of December 31, 2025, Cellectis had cash and cash equivalents of $61.5 million and short-term investments of $147.1 million, with a current ratio of 0.84 and a cash ratio of 1.43, indicating liquidity sufficient to fund operations into the second half of 2027 [S1].
• The company’s ADSs are listed on Nasdaq under the ticker CLLS and ordinary shares on Euronext Growth Paris under ALCLS [S1].
• Cellectis has granted stock options to executive officers and directors in 2025, subject to vesting and performance conditions [S1].
• The company faces patent litigation risks related to its TALEN-based gene editing technology, including a lawsuit filed by Factor in 2025 alleging patent infringement [S1].
• Cellectis has not declared or paid dividends and has an accumulated deficit of approximately $72.4 million as of December 31, 2025 [S1].
• Recent news coverage includes initiation of coverage with buy recommendations by Clear Street and maintenance of outperform and buy ratings by Citizens, Jefferies, and Barclays, reflecting analyst interest [N2][N3][N4][N6].
• Cellectis announced a 'Smart CAR T' strategy at AACR-IO 2025 to enhance efficacy against solid tumors, indicating ongoing innovation in its product pipeline [N8].
• The company’s 2025 strategic course was boosted by the AstraZeneca deal, highlighting the importance of collaborations [N7].
• Search interest in Cellectis stock has spiked recently, indicating increased market attention [N1].